Corvus Pharmaceuticals (CRVS) Insider buying
3 open-market purchases of CRVS by Corvus Pharmaceuticals's executives and directors since May 2026, worth $333,689 in total, from SEC Form 4 filings.
Summary
The most recent: David Scott Moore, Director bought $250,236 on June 11, 2026.
The biggest buyer over the period is David Scott Moore (Director): 1 purchase, $250,236.
By year
| Year | Purchases | Value |
|---|---|---|
| 2026 | 3 | $333,689 |
Biggest buyers
| Insider | Buys | Value |
|---|---|---|
| David Scott Moore Director | 1 | $250,236 |
| Richard A Miller Md President and CEO | 2 | $83,453 |
Every purchase
Newest first. From SEC Form 4 filings. Insider buying across the market.
Questions about Corvus Pharmaceuticals
Are Corvus Pharmaceuticals insiders buying the stock?
3 open-market purchases of CRVS by Corvus Pharmaceuticals's executives and directors since May 2026, worth $333,689 in total, from SEC Form 4 filings. The most recent: David Scott Moore, Director bought $250,236 on June 11, 2026.
What counts as insider buying here?
Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.
From Corvus Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.